Experienced in Riboflavin Transporter Deficiency Neuronopathy

Emilien Bernard

Lyon, FR 
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Lyon, FR 
OverviewLocationsClinical Research

Overview

Emilien Bernard practices in Lyon, France. Mr. Bernard is rated as an Experienced expert by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Riboflavin Transporter Deficiency Neuronopathy, and Paraplegia.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Riboflavin Transporter Deficiency Neuronopathy.

Gender
Male

Locations

Lyon, France
Other Locations
Bron, France
Tours, France
Auvergny, France
Infectiologie 151, Route De St Antoine De Ginestière, Nice, 06200, France
UMR5520 & U1044 Inserm, 43, Boulevard Du 11-Novembre-1918, Villeurbanne, 69100, France
Place Victor Pauchet, Amiens, 80054, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Electrophysiological Evaluation of Voluntary Attention
Electrophysiological Evaluation of Voluntary Attention
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Other
Study Phase: Not Applicable
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drugs: Riluzole, IL-2
Study Phase: Phase 2
View 2 Less Clinical Trials

70 Total Publications

Serum Neurofilament Light Chain Correlates With Clinical Severity and Predicts Mortality in Anti-IgLON5 Disease.
Serum Neurofilament Light Chain Correlates With Clinical Severity and Predicts Mortality in Anti-IgLON5 Disease.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bernard's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile